uniQure N.V. (NASDAQ:QURE) Given Consensus Recommendation of “Moderate Buy” by Brokerages

Shares of uniQure N.V. (NASDAQ:QURE) have been assigned a consensus recommendation of “Moderate Buy” from the thirteen brokerages that are presently covering the company, MarketBeat reports. One equities research analyst has rated the stock with a sell recommendation, two have given a hold recommendation and ten have given a buy recommendation to the company. The average 12 month price objective among brokerages that have issued ratings on the stock in the last year is $60.8182.

Several brokerages recently commented on QURE. Wall Street Zen lowered shares of uniQure from a “hold” rating to a “sell” rating in a research report on Monday, December 8th. Weiss Ratings restated a “sell (d-)” rating on shares of uniQure in a report on Wednesday, October 8th. HC Wainwright decreased their target price on uniQure from $110.00 to $70.00 and set a “buy” rating for the company in a research report on Tuesday, November 4th. Wells Fargo & Company cut their price target on uniQure from $80.00 to $60.00 and set an “overweight” rating on the stock in a research note on Wednesday, November 12th. Finally, Chardan Capital restated a “buy” rating and issued a $53.00 target price on shares of uniQure in a research note on Thursday, December 4th.

Insider Buying and Selling

In related news, CFO Christian Klemt sold 15,000 shares of the business’s stock in a transaction that occurred on Friday, September 26th. The shares were sold at an average price of $55.00, for a total transaction of $825,000.00. Following the transaction, the chief financial officer directly owned 217,730 shares of the company’s stock, valued at approximately $11,975,150. The trade was a 6.45% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, Director Jack Kaye sold 38,810 shares of the company’s stock in a transaction dated Tuesday, November 4th. The stock was sold at an average price of $30.34, for a total value of $1,177,495.40. Following the completion of the transaction, the director directly owned 20,439 shares in the company, valued at approximately $620,119.26. The trade was a 65.50% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. In the last 90 days, insiders sold 85,244 shares of company stock valued at $2,859,386. Company insiders own 4.79% of the company’s stock.

Institutional Inflows and Outflows

Institutional investors have recently bought and sold shares of the company. Private Trust Co. NA acquired a new stake in uniQure in the 3rd quarter valued at $28,000. Jones Financial Companies Lllp grew its position in uniQure by 509.0% during the 3rd quarter. Jones Financial Companies Lllp now owns 609 shares of the biotechnology company’s stock worth $33,000 after acquiring an additional 509 shares during the last quarter. CIBC Private Wealth Group LLC bought a new stake in shares of uniQure during the third quarter worth $50,000. FNY Investment Advisers LLC increased its stake in shares of uniQure by 76.7% in the third quarter. FNY Investment Advisers LLC now owns 1,654 shares of the biotechnology company’s stock valued at $96,000 after buying an additional 718 shares in the last quarter. Finally, Knott David M Jr bought a new position in shares of uniQure in the third quarter valued at about $117,000. Institutional investors own 78.83% of the company’s stock.

uniQure Price Performance

Shares of QURE opened at $25.31 on Thursday. The firm has a market capitalization of $1.58 billion, a price-to-earnings ratio of -5.77 and a beta of 0.59. The firm’s fifty day simple moving average is $35.12 and its 200-day simple moving average is $26.80. uniQure has a twelve month low of $7.76 and a twelve month high of $71.50. The company has a current ratio of 7.12, a quick ratio of 7.12 and a debt-to-equity ratio of 0.23.

uniQure (NASDAQ:QURE) last issued its quarterly earnings data on Monday, November 10th. The biotechnology company reported ($1.38) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.85) by ($0.53). uniQure had a negative return on equity of 373.73% and a negative net margin of 1,492.90%.The firm had revenue of $3.70 million for the quarter, compared to analysts’ expectations of $4.46 million. Equities analysts forecast that uniQure will post -3.75 EPS for the current fiscal year.

uniQure Company Profile

uniQure N.V. is a biotechnology company focused on the development and commercialization of gene therapies for patients with severe medical needs. Using its proprietary adeno‐associated viral (AAV) vector platform, the company designs single‐dose treatments aimed at addressing the underlying genetic causes of disease rather than solely managing symptoms. Its most advanced program, Hemgenix® (etranacogene dezaparvovec), received regulatory approval in the United States and Europe for adult patients with hemophilia B, marking one of the first gene therapies for a bleeding disorder to reach the market.

Beyond hemophilia B, uniQure’s pipeline includes preclinical and clinical-stage candidates targeting rare and debilitating conditions such as aromatic l-amino acid decarboxylase (AADC) deficiency, Huntington’s disease, and Parkinson’s disease.